✨ 𝗗𝗜𝗔𝗟𝗢𝗚𝗨𝗘𝗦 | What are some recent advancements in muscle pain treatment? Learn about the use of Magnetic Resonance Elastography (MRE) in researching Myofascial Pain Syndrome (MPS), a prevalent pain disorder. 🗓️ 10 May, 5.30pm (GMT+8) 🎟️ Attend online or in-person👇

Women are more prone to left ventricular shear stiffness in the heart as they age, according to studying using magnetic resonance elastography. pubs.rsna.org/doi/10.1148/ry…

ICYMI: New clinical guidelines from AASLD on staging liver fibrosis using imaging techniques in MASLD and MASH patients 👉AASLD identifies VCTE, SWE, and MRE as the only imaging techniques suitable for assessing fibrosis noninvasively 👉MRE was the most accurate for F2

DYK: Paris has 13 locations where you can get an MRE for liver fibrosis assessment 🌍 With over 2500 locations worldwide - including more locations in the US (1200+) than Fibroscan (800+), MRE is widely available and ready for clinical use Find a location near you:

Great piece by Mayo Clinic press mcpress.mayoclinic.org/living-well/ha…

Resoundant appoints Kay Pepin, PhD (Kay Pepin) as Chief Operating Officer resoundant.com/single-post/re…

Some key points about the MAESTRO-NASH trial for Rezdiffra: ✅ MRE was the most accurate NIT for identifying F2-F3 patients ✅ MRE was the only NIT to significantly monitor fibrosis response ❌ VCTE was not significant for monitoring response (p = 0.66) ✅ PDFF was only

Great study on the ability of tissue stiffness via MR Elastography to risk stratify patients for progression to cirrhosis and liver decompensation in ALD patients, independent of histology 🟢Key point: every kPa increase in MRE is associated with increased risk in liver-related

Congrats to Madrigal ($MDGL) on a great Rezdiffra launch! There was a question on MRE/PDFF access. Let me provide some numbers: #livertwitter ir.madrigalpharma.com/news-releases/…

Four years of work- Key paper to read Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA gut.bmj.com/content/early/… AASLD EASLnews INASL Daniel Huang Federica Tavaglione UCSD Gastroenterology

Thank you Consultant360 for putting this interview together with ⁦Mazen Noureddin, MD, MHSc⁩ and ⁦Amreen Dinani⁩ to discuss this 🔥 topic! Resmetirom and NITs! ⁦Madrigal Pharmaceuticals⁩ ⁦Echosens⁩ ⁦Resoundant⁩ ⁦Arizona Liver Health⁩ consultant360.com/videos/initiat…

Study Identifies Most Accurate Noninvasive Method for Diagnosing MASH physiciansweekly.com/study-identifi… #livertwitter Naim Alkhouri Jörn Schattenberg Journal of Hepatology Echosens

Thanks gutsy journal Gut Journal and Emad El-Omar for highlighting our paper funded by NIH - important data regarding what is the prevalence of cirrhosis among obese in United States 🇺🇸!!

⚡️You've read updated guidance from AASLD that says MRE is the most accurate for liver fibrosis staging. ⚡️You've seen the news about a breakthrough new therapy called Rezdiffra. ⚡️You've also seen nearly all payers identify MRE and PDFF in their prior authorization criteria,

#tweetorial #livertwitter 1/ What is the prevalence of #MASLD subcategories in a real world population? A prospective study conducted at MASLD Research Center UCSD Gastroenterology with Rohit Loomba Gut Journal Emad El-Omar AASLD EASLnews INASL Patty Maysent Chris Longhurst

#GUTImage from the paper by Alex Yang et al on "Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA" via bit.ly/4fRh0Ub @drmaralmd Rohit Loomba Mónica Tincopa MD MSc Daniel Huang

What is MRI-PDFF? A #MedTwitter #livertwitter #tweetorial (with GIFs)

Who to treat for MASH with fibrosis? Handy guide 👇

Handy guide 🎯

#GUTImage from the paper by Alex Yang et al on "Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA" via bit.ly/4fRh0Ub @drmaralmd Rohit Loomba Mónica Tincopa MD MSc Daniel Huang